KING OF PRUSSIA, PA — United BioSource LLC has acquired Vancouver-based Evidinno Outcomes Research Inc., a move that sharply expands its capabilities in real-world evidence, health economics, and advanced outcomes research as biopharma companies face mounting pressure to prove value beyond clinical trials.
The acquisition brings Evidinno’s specialized expertise in epidemiology, evidence synthesis, and economic modeling under the UBC umbrella, creating what executives describe as a more powerful, end-to-end platform for late-stage and post-approval research.
United BioSource LLC partners with biopharmaceutical companies to modernize evidence development and patient access pathways, using technology-enabled study design and data acquisition to demonstrate safety, effectiveness, and value in real-world settings. The addition of Evidinno deepens that offering with regulatory- and health technology assessment–grade analytics increasingly demanded by payers and regulators worldwide.
Evidinno Outcomes Research Inc. is known for its work in real-world evidence generation, comparative effectiveness research, network meta-analyses, and health economic modeling. Its team of epidemiologists, health economists, and research scientists also delivers AI-enabled, expert-led literature reviews and HTA dossier development across the product lifecycle.
“Evidinno’s scientific rigor and technology-enabled workflows deepen our ability to curate fit-for-purpose evidence and health economic and outcomes insights for our clients,” said Aaron Berger, senior vice president of evidence development solutions at UBC. He said the combination is designed to help sponsors answer critical questions about treatment safety and effectiveness while transforming how evidence is generated and applied.
Evidinno Chief Executive Officer Mir Sohail Fazeli said the deal significantly broadens the reach of the firm’s scientific and methodological work. By pairing Evidinno’s HTA- and regulatory-grade evidence synthesis with UBC’s global platform, he said, the combined organization is positioned to deliver decision-ready insights that support sponsors and improve patient outcomes worldwide.
Under the terms of the transaction, Evidinno will operate as a wholly owned subsidiary of UBC, with an integrated service model spanning clinical development through post-approval commercialization.
Fairmount Partners served as exclusive financial advisor to Evidinno.
The deal reflects a broader shift in the life sciences sector, where real-world data and economic evidence are becoming as critical as clinical trial results in determining whether new therapies reach patients—and whether they succeed once they do.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.